Opendata, web and dolomites

PULTAR

Delivery of PULmonary Therapeutics through TARgetted Delivery using Phononics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PULTAR project word cloud

Explore the words cloud of the PULTAR project. It provides you a very rough idea of what is the project "PULTAR" about.

respiratory    235    disease    healthcare    amount    380b    biologics    gt    limitations    gene    efficacy    cystic    ultrasonic    epithelium    treating    anatomical    cells    selective    therapies    substantial    aerosol    nebuliser    diseases    barriers    data    patients    model    mu    monodisperse    worldwide    million    team    outcomes    according    accepted    types    difficult    shown    chronic    medicines    suffer    aerosols    industry    vascular    forms    inhalation    genes    treatment    routes    asthma    dalys    innovation    drug    reduce    50m    prototype    create    closely    arterial    generally    similarly    proprietary    improves    droplet    market    regions    hypertension    therapy    tissue    extremely    strand    precise    transits    pulmonary    therapeutic    wisdom    sizes    start    again    rna    mouse    deaths    delivered    3m    nebulisation    clinical    fibrosis    medicine    lung    quality    people    commercial    enhanced    appealing    droplets    obstructive    64m    lungs   

Project "PULTAR" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF GLASGOW 

Organization address
address: UNIVERSITY AVENUE
city: GLASGOW
postcode: G12 8QQ
website: www.gla.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙791 €
 EC max contribution 149˙791 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF GLASGOW UK (GLASGOW) coordinator 149˙791.00

Map

 Project objective

According to the WHO 235 million people suffer from asthma and 64M people have chronic obstructive pulmonary disease, leading to 3M deaths per year worldwide. The cost of treating patients with all forms of lung disease is ~ €380B p.a., leading to the loss of >50M DALYS. Generally, patients with such respiratory diseases are treated by inhalation of medicines within aerosols, where the therapy (including medicine or biologics used in gene therapy) can be targeted directly to the lung. The accepted wisdom is that such pulmonary delivery requires aerosol droplet sizes of between 1 and 5 μm. We have now shown that by using a new ultrasonic technology, we can create monodisperse aerosol droplets, which could be used for therapeutic delivery of medicines, genes and RNA to specific regions in the lungs. In one strand of the work we aim to demonstrate that this precise nebulisation technology improves the efficacy of treatment through enhanced drug uptake. In a second strand, we will demonstrate selective targeting of different tissue types in the lungs. For example, the epithelium in cystic fibrosis patients is currently extremely difficult to access leading to limitations in the amount and quality of data obtained for pre-clinical and clinical gene therapies. Similarly, targeting vascular cells is an appealing treatment for patients with pulmonary arterial hypertension, although, again, effective delivery necessitates that the therapeutic system transits defined and substantial anatomical barriers. The overall aim is to demonstrate that this new technology can define routes to new therapies, improve clinical outcomes and reduce healthcare costs. To achieve this we will develop a prototype nebuliser based upon proprietary technology and show that different medicines and gene therapies can be delivered effectively to the lungs of a model mouse. We will also start to build a commercial team and work closely with industry to deliver impact and innovation to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PULTAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PULTAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

inhibiTOR (2020)

Novel selective mTORC1 inhibitors

Read More  

TORYD (2020)

TOpological many-body states with ultracold RYDberg atoms

Read More  

AllergenDetect (2019)

Comprehensive allergen detection using synthetic DNA libraries

Read More